Stock Analysis
Bausch Health Companies Inc. (BHC) Stock Analysis
Bausch Health Companies Inc. (BHC) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Bausch Health Companies Inc. (BHC) currently has an AIQ Score of 76/100, indicating a bullish setup. Quality is the strongest factor at 100/100. Risk is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BHC at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $8.20 |
| AIQ Score | 76/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $2.42B |
| P/E Ratio (TTM) | -2.19 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $0.67 |
| Revenue (quarter ended 2026-06-30) | $2.85B |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.38 |
| Volume | 8.87M |
| 52-week range | $4.33-$9.04 |
| RSI 14 | 78.53 |
| 50-Day SMA | $6.21 |
| 200-Day SMA | $5.70 |
| Analyst Price Target | $9.00 |
| Next Earnings | Feb 17, 2027 |
BHCBausch Health Companies Inc.
Healthcare / Drug Manufacturers - Specialty & Generic
Leader
Sector Leader
Latest quote
- Momentum79
- Value75
- Quality100
- Risk resilience24
- Sentiment57
BHC Stock Analysis Summary
Bausch Health Companies Inc. (BHC) currently has an AIQ Score of 76/100, indicating a bullish setup. Quality is the strongest factor at 100/100. Risk resilience is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, BHC has AIQ Score of 76/100 with Quality base of 100/100 and fading Risk resilience at 24/100. Wait for component alignment before adding exposure.
Quality (100/100) leads while Risk resilience (24/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -7.97% stock move · BHC classified in Drug Manufacturers - Specialty & Generic.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BHC Bullish or Bearish Right Now?
BHC currently has a bullish overall setup. Quality is the strongest factor at 100/100, while Risk Resilience is weakest at 24/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 100/100.
- - Momentum is constructive at 79/100.
- - Price is +43.52% above its 50-day SMA.
- - Analyst target implies +9.76% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (38 vs 7).
- - Risk Resilience is weak at 24/100.
Current Consensus
BHC's Technical Analysis Consensus is currently Strong Buy, with 38 buy, 0 neutral, and 7 sell votes. BHC's 14-day RSI is 78.53, which places the stock in an overbought momentum range. BHC's beta is 0.38, indicating lower market sensitivity than the broad market.
What Changed in BHC?
The largest recent change in BHC is Risk Resilience moving down by 11.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the BHC Outlook?
The current bullish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BHC Decision Framework
Public evidence layers, setup checks, and risk context for Bausch Health Companies Inc..
Bausch Health Companies Inc. (BHC) Stock Analysis
Bausch Health Companies Inc. has an AIQ Score of 76/100 in a Bullish regime. Quality is strongest at 100/100. Beta is 0.37, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BHC is in a Bullish AIQ regime with score 76/100. |
| Signal Conflict | The primary conflict is that quality leads at 100/100 while risk lags at 24/100. |
| Factor Evidence | Momentum 79/100 · Value 75/100 · Quality 100/100 · Risk 24/100 · Sentiment 57/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 100/100.
Momentum is 79/100 and RSI (14) is 78.5.
BHC is in a Bullish regime at 76/100.
Risk factor is 24/100 with beta 0.37 and annual volatility 63.62%.
Current conflict: quality leads at 100/100 while risk lags at 24/100.
BHC Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BHC Fundamentals
BHC valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BHC Technical Analysis
BHC technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BHC Stock Catalysts
Track BHC earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BHC Dividend Analysis
BHC dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BHC Financial Data
BHC revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BHC Risk Analysis
BHC volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BHC Stock News
BHC stock news, market tone, recent headlines, and catalyst context.
BHC vs Large Cap Pharma Peers
Current peer cohort: BHC · BIIB · BMRN · BMY · BNTX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BHC Current stock | 76/100 | 75/100 | 79/100 | 24/100 | 0.88 | 63.62% | Current |
| BIIB Biogen | 63/100 | 61/100 | 82/100 | 47/100 | 1.59 | 34.28% | BHC vs BIIB |
| BMRN BioMarin Pharmaceutical | 48/100 | 38/100 | 52/100 | 54/100 | 0.35 | 35.36% | BHC vs BMRN |
| BMY Bristol-Myers Squibb | 61/100 | 65/100 | 55/100 | 41/100 | 1.3 | 28.39% | BHC vs BMY |
| BNTX BioNTech | 45/100 | 35/100 | 27/100 | 65/100 | -0.17 | 46.86% | BHC vs BNTX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BHC
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BHC
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BHC Stock FAQ
What is BHC stock price today?
Bausch Health Companies Inc.'s current stock price is $8.20. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BHC bullish or bearish right now?
BHC's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BHC's market cap?
BHC's market cap is $2.42B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BHC's current P/E ratio?
BHC's current P/E ratio is -2.19 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BHC's RSI?
BHC's 14-day RSI is 78.53 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BHC above its 50-day and 200-day moving averages?
BHC is 43.52% from its 50-day SMA and 56.42% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BHC's next earnings date?
BHC's next earnings date is currently listed as Feb 17, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BHC pay a dividend?
BHC's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.